press releases

Lysogene Enters into a Loan Agreement of €15 million with the European Investment Bank (EIB)

Lysogene Enters into a Loan Agreement of €15 million with the European Investment Bank (EIB) 150 150 Lysogene

The financing will enable Lysogene to accelerate the development of its gene therapy platformThe loan…

Lysogene awarded Innovation Passport by the UK MHRA for the GM1 gangliosidosis program

Lysogene awarded Innovation Passport by the UK MHRA for the GM1 gangliosidosis program 150 150 Lysogene

First step in the recent UK MHRA initiative to accelerate the development and access to…

Lysogene Receives MHRA and Research Ethics Committee Approvals to Initiate the Gene Therapy Clinical Trial in the UK with LYS-GM101 for the Treatment of GM1 Gangliosidosis

Lysogene Receives MHRA and Research Ethics Committee Approvals to Initiate the Gene Therapy Clinical Trial in the UK with LYS-GM101 for the Treatment of GM1 Gangliosidosis 150 150 Lysogene

LYS-GM101 is Lysogene’s second CNS gene therapy program to enter clinic Trial enrollment expected to…

Lysogene secures a €4.3 million non-dilutive financing from Bpifrance to support its development

Lysogene secures a €4.3 million non-dilutive financing from Bpifrance to support its development 150 150 Lysogene

Financing composed of a €3 million R&D innovation loan and a 1.3 million reimbursable advance…

Lysogene announces a presentation of its LYS-GM101 program at the ESGCT 2021

Lysogene announces a presentation of its LYS-GM101 program at the ESGCT 2021 150 150 Lysogene

Paris, France — 18 october 2021 at 06:00 pm CEST — Lysogene (FR0013233475 – LYS),…

Lysogene Reports its Cash Position as of 30 September 2021

Lysogene Reports its Cash Position as of 30 September 2021 150 150 Lysogene

• Cash and cash equivalents of €9.5 million as of 30 September 2021 Paris, France…

LYSOGENE Reports First Half 2021 Financial Results and Provides Operational Update

LYSOGENE Reports First Half 2021 Financial Results and Provides Operational Update 150 150 Lysogene

• In the first half 2021, Lysogene advanced and extended its development pipeline• Cash and…

Lysogene Announces First Patient in the United States Dosed with LYS-GM101 Investigational Gene Therapy for the Treatment of GM1 Gangliosidosis

Lysogene Announces First Patient in the United States Dosed with LYS-GM101 Investigational Gene Therapy for the Treatment of GM1 Gangliosidosis 150 150 Lysogene

Second patient treated in the global adaptative-design clinical trial with LYS-GM101Ongoing enrollment of a total…

Lysogene Reports its Cash Position as of 30 June 2021

Lysogene Reports its Cash Position as of 30 June 2021 150 150 Lysogene

Cash and cash equivalents of €15.0 million[1] as of 30 June 2021 [1] Unaudited figure…

Lysogene Announces FDA Fast Track Designation for LYS-GM101 Gene Therapy for the Treatment of GM1 Gangliosidosis

Lysogene Announces FDA Fast Track Designation for LYS-GM101 Gene Therapy for the Treatment of GM1 Gangliosidosis 150 150 Lysogene

Paris, France — 08 July 2021 at 06:00 pm CET — Lysogene (FR0013233475 – LYS), a…

Lysogene COVID-19 update

Get In Touch

Don’t hesitate to contact us if you need more help.